First Heartland Consultants Inc. Sells 104 Shares of Amgen Inc. (NASDAQ:AMGN)

First Heartland Consultants Inc. lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,445 shares of the medical research company’s stock after selling 104 shares during the quarter. First Heartland Consultants Inc.’s holdings in Amgen were worth $788,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Edmond DE Rothschild Holding S.A. lifted its position in Amgen by 63.5% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 2,230 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 866 shares in the last quarter. Angeles Wealth Management LLC bought a new position in Amgen in the 1st quarter valued at about $210,000. Delta Investment Management LLC lifted its position in Amgen by 8.6% in the 1st quarter. Delta Investment Management LLC now owns 1,842 shares of the medical research company’s stock valued at $524,000 after acquiring an additional 146 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its stake in Amgen by 41.3% in the 1st quarter. Beacon Investment Advisory Services Inc. now owns 41,950 shares of the medical research company’s stock valued at $11,927,000 after buying an additional 12,268 shares during the last quarter. Finally, Kingsview Wealth Management LLC increased its stake in shares of Amgen by 10.1% during the 1st quarter. Kingsview Wealth Management LLC now owns 63,452 shares of the medical research company’s stock worth $18,041,000 after purchasing an additional 5,819 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $298.84 on Wednesday. The stock has a market cap of $160.64 billion, a PE ratio of 38.26, a PEG ratio of 2.90 and a beta of 0.60. The company’s fifty day moving average is $323.37 and its 200 day moving average is $318.07. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the company earned $4.96 EPS. Research analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. UBS Group cut their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Finally, TD Cowen raised their price objective on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average price target of $333.50.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.